calling all coworkers

The Ion Houston announces opening of its coworking space

The Ion has officially opened its coworking space on the second floor of the Midtown building. Rendering courtesy of Common Desk

The Ion Houston's coworking space — roughly four times the size of a typical Walgreens drugstore — opened this week ready to welcome its pre-leased tenants and potential coworkers alike.

The coworking space, Common Desk, occupies 58,400 square feet on the second floor of The Ion. That represents about one-fifth of the 266,000-square-foot Ion complex.

Amenities at Common Desk include craft coffee from local purveyors, unlimited conference room bookings, access to all shared areas on the second floor, private chat booths, full kitchens, and break areas.

Other tenants at The Ion include Chevron Technology Ventures and Microsoft. The Ion opened earlier this year, occupying the former Sears store in Midtown following a $100 million conversion. It's part of the 16-acre Innovation District, being developed by Rice University and the City of Houston.

"We can't wait for our new Common Desk tenants and members across their network to experience the magic that's being made here," Jan Odegard, executive director of The Ion, says in a news release. "Just as The Ion, alongside developer Rice Management Company, set out to build an innovation community and hub different from anything the nation has ever seen, Common Desk set out to build its biggest and most innovative space yet."

Dallas-based Common Desk specializes in flexible office space. Its location at The Ion is the company's largest flex office space to date.

"Common Desk has joined the ranks of some of the nation's top companies to cultivate an authentic, game-changing community destined to transform Houston's innovation ecoscape," says Dawson Williams, head of growth and partnerships at Common Desk.

Members of the Common Desk location at The Ion also can use the company's three other coworking spaces in Houston, as well as it locations in Austin, Dallas-Fort Worth, and North Carolina.

Common Desk's coworking space has several options for leasing. Photos courtesy of Common Desk

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted